Log In
Print
BCIQ
Print
Print this Print this
 

F598, SAR279356

  Manage Alerts
Collapse Summary General Information
Company Alopexx Pharmaceuticals LLC
DescriptionHuman mAb against poly-N-acetyl glucosamine (PNAG)
Molecular Target Poly-N-acetyl glucosamine (PNAG)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationBacterial infection
Indication DetailsTreat and prevent bacterial infection
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today